

Artrya signs US\$0.6M five-year contract with Tanner Health

U.S. Commercial launch of Salix® Coronary Anatomy platform - First U.S. Revenues

PERTH, Australia, 10 July 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce its first U.S. revenue with Tanner Health for the use of its Salix® Coronary Anatomy platform. This first revenue represents a major milestone for Artrya as it continues to transition to a revenue-stage business.

Key Points

- **First revenue in the U.S. for the use of Salix® Coronary Anatomy platform expected in current quarter**
- **Five-year commercial agreement signed with Tanner Health, value at US\$0.6M**
- **Agreement provides pathway for additional revenue from Salix® Coronary Plaque and Salix® Coronary Flow modules, post-FDA clearances**
- **Salix® to be integrated across Tanner Health's network of hospitals and cardiology practices**
- **Represents major milestone as Artrya transitions to revenue-generating phase in the U.S. market**

Following U.S. FDA 510(k) clearance in March 2025, the Salix® Coronary Anatomy platform will now be rolled out and be available for clinical use across Tanner Health's five hospitals, cardiovascular centres, and 30 physician practices.

The Commercial Agreement with Tanner Health provides a SaaS licence with a monthly subscription fee for Salix® Coronary Anatomy over 60 months and provides for future fee-per-scan revenues once additional modules such as Salix® Coronary Plaque and Salix® Coronary Flow receive FDA clearance, which are both eligible for U.S. reimbursement under Category 1 CPT codes.

John Konstantopoulos, Co-Founder and CEO of Artrya, said:

"This five-year agreement with Tanner Health is a major milestone for Artrya as it will deliver our first U.S. commercial revenues. Tanner Health's decision to adopt Salix® over other technologies highlights the strength of our platform and the trust we've built with their clinical teams.

Importantly, this collaboration provides a blueprint for future U.S. rollouts as we look to expand the adoption of our platform across hospital networks and prepare for additional product launches."

Loy Howard, president and CEO of Tanner Health, said:

"At Tanner Health, we are committed to bringing novel technology to support patient care. Having considered other technology, we believe Artrya's Salix® platform with its AI-powered, user friendly and near real-time outcomes, provides our clinicians with another key tool to help detect heart disease earlier and save lives. Since we first started our strategic partnership over a year ago, the team at Artrya has worked closely with our clinical and technology teams to support the clinical and commercial validation across our network. We're also proud to be chosen as the first U.S. health system to implement this innovative technology into our daily practice."

Commercial Agreement and first U.S. Clinical use of Salix® Coronary Artery platform

The Salix® Coronary Anatomy platform has been successfully integrated into Tanner Health's Picture Archiving and Communications System (**PACS**) and Electronic Medical Record (**EMR**) systems and will now be available for clinical use on their patients with known or suspected coronary artery disease who have undergone a coronary CT angiogram, as it gets rolled out across the network.

This successful integration also follows a lengthy validation and product enhancement process for the Salix® Coronary Anatomy platform in a test environment, with close collaboration between Tanner Health's IT Team and Artrya's Integration Team. As part of this, Dr Shazib Khawaja, MD, Chair of Tanner Heart and Vascular Centre and Chief of Interventional Cardiology, and Dr Ben Camp, MD, Chief Medical Officer of Tanner Health, were each instrumental in supporting the clinical utility of the Salix® platform.

Additionally, Artrya and Tanner Health have executed a Commercial Agreement to use Salix® Coronary Anatomy platform, as detailed below. Importantly, future modules such as the Salix® Coronary Plaque module, will be automatically available for clinical use once FDA clearance is received, increasing the revenue opportunity.

Artrya is actively progressing commercial discussions with additional U.S. hospital networks, including partners Northeast Georgia Health System, Cone Health, and health systems that will participate in the SAPPHIRE Study. The Company is also preparing for the FDA clearance and commercial launch of the Salix® Coronary Plaque module, which will further expand its platform offering and revenue base.

About Tanner Health

Tanner Health is a five-hospital non-profit health system providing convenient, personalized health care to communities across west Georgia and east Alabama. Tanner Health physicians and staff provide the latest technology and treatment options to advance the health of our patients. In addition to their regional hospitals and care centres, Tanner operates Tanner Medical Group, one of metro Atlanta's largest multi-specialty physician groups. Learn more at www.tanner.org

Material terms of the agreement

The full details of the Commercial Agreement are commercial in confidence, with the material points as follows:

- Commercial SaaS Licence Agreement for non-exclusive use of the Salix® Coronary Anatomy platform for clinical use
- Monthly subscription fee over the duration for use of the Salix® Coronary Anatomy platform
- Additional Salix® modules will be available for clinical use by Tanner Health, subject to FDA clearance
- Once additional Salix® modules receive FDA clearance, each CCTA scan analysed will attract a fee per scan, which will also be eligible for U.S. reimbursement under a Category 1 CPT code
- Five-year term for the agreement with standard provisions for events of default
- Termination with 30 days' notice with no cancellation fees
- Customary terms include security and privacy protocols, support levels, software upgrades.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com